

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	08/29/2003
CONVEYING PARTY DATA	
Name	Execution Date
Aventis Research & Technologies Verwaltungs GmbH	08/29/2003
RECEIVING PARTY DATA	
Name:	Aventis Pharma Deutschland GmbH
Street Address:	Industriepark Hoechst
City:	Frankfurt am Main
State/Country:	GERMANY
Postal Code:	D-65926
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6414431
CORRESPONDENCE DATA	
Fax Number:	(302)658-5614
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	302-888-6427
Email:	gcunningham@cbhl.com
Correspondent Name:	Grant D. Cunningham
Address Line 1:	The Nemours Building
Address Line 2:	1007 North Orange Street, P.O. Box 2207
Address Line 4:	Wilmington, DELAWARE 19899
ATTORNEY DOCKET NUMBER:	14113-15
NAME OF SUBMITTER:	Grant D. Cunningham
Total Attachments: 4 source=merger2#page1.tif	

CH \$40.00 6414431


500282942

PATENT
REEL: 019331 FRAME: 0556

source=merger2#page2.tif
source=merger2#page3.tif
source=merger2#page4.tif

Declaration

Frankfurt, March 7, 2005

- 
1. Hoechst Research & Technology Deutschland GmbH & Co. KG (registered number HRA 28517) was a limited partnership established by Hoechst Aktiengesellschaft as its sole limited partner and Hoechst Research & Technology Deutschland Verwaltungs GmbH (then with its registered office in Frankfurt am Main, registered number HRB 39459) as its sole general partner.
 2. On 29 May 1998 Hoechst Research & Technology Deutschland Verwaltungs GmbH changed its name to Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459) and on 4 November 1998 Hoechst Research & Technology Deutschland GmbH & Co. KG changed its name to Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517).
 3. With legal effect as of 31 May 2003 and registered with the commercial register on 18 June 2003 Hoechst Aktiengesellschaft, as sole limited partner in Aventis Research & Technologies GmbH & Co KG withdrew from the limited partnership leading to the dissolution of the partnership Aventis Research & Technologies GmbH & Co KG. All of its assets and obligations were transferred by operation of law to the sole general partner Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459), which became the legal successor of the limited partnership.
 4. With effect as of registration on 29 August 2003, Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459) was merged into Aventis Pharma Deutschland GmbH as the transferee company with Aventis Pharma Deutschland GmbH becoming the legal successor to Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459) and due to the previous transfer of assets and obligations accordingly the final legal successor to Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) and to all of the assets and obligations of Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) and Aventis Pharma Deutschland GmbH assuming by operation of law the obligations of Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) in respect of the Intellectual Property.





5. On 1 September 2005 Aventis Pharma Deutschland GmbH (registered number HRB 40661) changed its name to Sanofi-Aventis Deutschland GmbH

For and on behalf of
Sanofi-Aventis Deutschland GmbH

Signed by:

Name:


Dieter Kohl
Director and CFO


ppa. Dr. Dirk Kruse
Corporate Counsel

Nr. 347/2006 der Urkundenrolle

Der Notar versichert, daß er die Beteiligten nach einer Vorbefassung im Sinne des § 3 Abs. 1 Satz 1 Nr. 7 BeurkG gefragt hat. Die Frage wurde verneint.

The Notary Public confirms, that he has asked the participants, if there has been a prior involvement in the meaning of § 3 section 1 sentence 1 No. 7 BeurkG (Law on Notarization). This question was answered in the negative.

Vorstehende, vor mir anerkannte Unterschriften der Herren

I hereby certify that Messrs.

1. Geschäftsführer Dieter Kohl, Idstein,
2. Prokurist Dr. Dirk Kruse, Bad Homburg

beglaubige ich hiermit. Sie sind mir persönlich bekannt.

have affixed the above signatures. They are personally known to me.

Gleichzeitig bescheinige ich aufgrund des mir vorliegenden beglaubigten Handelsregistrauszuges des Amtsgerichts Frankfurt am Main - HR B 40661 - über die SANOFI-AVENTIS DEUTSCHLAND GMBH in FRANKFURT AM MAIN, daß die Herren

At the same time I confirm that according to the duly certified extract of the Commercial Register of the District Court of Frankfurt am Main, on SANOFI-AVENTIS DEUTSCHLAND GmbH of FRANKFURT AM MAIN, which is before me, -HR B 40661- Messrs.


1. Dieter Kohl,
-als Geschäftsführer-
2. Dr. Dirk Kruse
-als Prokurist-

1. Dieter Kohl,
-as General Manager-
2. Dr. Dirk Kruse,
-as registered authorized signatory-

der Sanofi-Aventis Deutschland GmbH zur gemeinsamen Vertretung der Gesellschaft berechtigt sind.

of Sanofi-Aventis Deutschland GmbH are authorized to jointly represent the said Corporation in legally binding manner.

Frankfurt am Main, den 13. März 2006



Friedrich, Notar

Kostenrechnung :

Wert : 10.000,-- EUR	
Gebühr §§ 141, 32, 45 Kost.O.	13,50 EUR
Gebühr § 150 Kost.O.	13,-- EUR
Steuer 16 %	4,24 EUR
	<u>30,74 EUR</u>
	=====

Notar

APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Land: Bundesrepublik Deutschland
Diese öffentliche Urkunde
2. ist unterschrieben von Klaus Peter Friedrich
3. in seiner Eigenschaft als amtlich bestellter Notar
4. sie ist versehen mit dem Siegel/Stempel des(der)
Notars



Bestätigt

5. in Frankfurt/Main
6. am 26.04.07
7. durch den Herrn Präsidenten des Landgerichts
8. unter Nr. 91 Ea A 4081
9. Siegel/Stempel
10. Unterschrift



K. P. Friedrich
i.V. Franke

